Bicycle Therapeutics (BCYC) PT Raised to $19 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Wall St futures mixed as Apple falls on margin warning, midterm results awaited
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BCYC Hot Sheet
Price: $3.62 --0%
Rating Summary:
13 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
13 Buy, 5 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
Goldman Sachs analyst Graig Suvannavejh raised the price target on Bicycle Therapeutics (NASDAQ: BCYC) to $19.00 (from $17.00) while maintaining a Buy rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs upgrades Sirius XM Radio to Buy with $37 target
- Bicycle Therapeutics (BCYC) PT Lowered to $10 at Jefferies
- Tower Semiconductor (TSEM) PT Lowered to $235 at Mizuho
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Goldman SachsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
